Opdivo, Keytruda Hit Again As Japan Revises Prices
Executive Summary
Immuno-oncology drugs Opdivo and Keytruda will have their prices cut in the next regular Japanese price revision in April, while some other novel and big-selling products will also feel the heat under a revised framework.
You may also be interested in...
Nichi-Iko Aims For ‘Commanding Presence’ In Japan Generics Via Eisai Alliance
Eisai has become the latest R&D-based pharma company in Japan to offload its non-innovative products as it seeks to maximize their sales and focus more on novelty and, by implication, the rewards this can bring under Japan’s evolving reimbursement pricing system.
Nichi-Iko Aims For ‘Commanding Presence’ In Japan Generics Via Eisai Alliance
Eisai has become the latest R&D-based pharma company in Japan to offload its non-innovative products as it seeks to maximize their sales and focus more on novelty and, by implication, the rewards this can bring under Japan’s evolving reimbursement pricing system.
Rival For Opdivo As Keytruda Launches For NSCLC In Japan At Same Daily Price
Opdivo has a new rival in the lung cancer setting in Japan following the reimbursement and launch of Keytruda at the same daily price.